Evidence map›Paper›PMID 41628346›Full record

ArticleBlood advances2026

Alloantibody IgG subclasses have differential activity in clearing transfused platelets in mice.

Elizabeth L Frost, Arijita Jash, Ariel M Hay, Robert Brink, Angelo D'Alessandro, Monika Dzieciatkowska, James C Zimring

Abstract read
In one paragraph

Article in Blood advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Elizabeth L FrostBeirne Carter Immunology Center, University of Virginia, Charlottesville VA.ORCID 0009-0007-7055-5879
Arijita JashBeirne Carter Immunology Center, University of Virginia, Charlottesville VA.ORCID 0000-0001-9613-4932
Ariel M HayBeirne Carter Immunology Center, University of Virginia, Charlottesville VA.ORCID 0000-0002-9003-6415
Robert BrinkGarvan Institute of Medical Research, Sydney, Australia.ORCID 0000-0002-9586-3655
Angelo D'AlessandroDepartment of Biochemistry and Molecular Genetics, University of Colorado, Aurora, CO.ORCID 0000-0002-2258-6490
Monika DzieciatkowskaDepartment of Biochemistry and Molecular Genetics, University of Colorado, Aurora, CO.ORCID 0000-0002-9947-2520
James C ZimringBeirne Carter Immunology Center, University of Virginia, Charlottesville VA.ORCID 0000-0002-1063-4010

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

abstractPlatelet transfusion is a necessary life-sustaining therapy for extreme thrombocytopenia from multiple etiologies. However, refractoriness develops in some patients such that transfused platelets are rapidly cleared and refractory patients are at risk for catastrophic hemorrhage. One cause of refractoriness is humoral immunization to major histocompatibility complex I (MHC-I) alloantigens. However, ∼50% of patients with alloantibodies to MHC-I do not become refractory. The factors that determine whether an alloimmunized patient is refractory remain undefined. Both mice and humans encode 4 distinct immunoglobulin G (IgG) subclasses, each with different effector function characteristics. In this article, we forward the hypothesis that IgG subclass composition of alloantisera affects refractoriness. A novel panel of mice was generated with mutated effector function for different murine IgG subclasses. Elimination of effector function of IgG2c (but not IgG1 or IgG2b) eliminated the ability of alloantisera to clear transfused platelets. Together, these data demonstrate the differential platelet-clearing activity of distinct IgG subclasses in vivo and support the hypothesis that differences in IgG subclass affect whether alloimmunization results in refractoriness to platelet transfusion.

Indexed as

Blood PlateletsImmunoglobulin GIsoantibodiesPlatelet TransfusionAnimalsHumansMiceImmunoglobulin GIsoantibodies

Identifiers

PMID41628346
PMCPMC13094438

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.